Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) T.ATE


Primary Symbol: ATBPF

Healthcare
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Incompetent CEO
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(178)
•••
Post by Layth1990on Mar 05, 2021 12:32pm
253 Views
Post# 32728956

Incompetent CEO

Incompetent CEO

Everything were excuted in a sh**y way. In askbio, Dan said no dilution and then he did "bought deal" which ruined the nuance momentum. Also, we still have probably another dilution for IP With holding. He screwed as well anyone who invested with the bought deal which was at 6cad. 

now they are adding after screwing the momentum and probably ip dilution will come at cheap prices for him and wallace. So much manipulation, i lost interest in ate because of what i mentioned above. We have a great product but not the right ceo and directors. I don't think they will get the company to the right valuation because of their greed. 

i don't thinjwe will have another partners because they did dilute us which means no future partners for funding. 

oh why reverse split if not you are not uplistong on nasdaq ? What are you doing? You gave us a morohine shot by upgrading the OTC. What a joke

you have no excuse for more delays. Us cases are way to down from 400k to 60k.i'm sure you will come up with something.

we need someone who gets things done, honest and with integrity. Your greed will kill everyone and this beautiful platform

 

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities